{
    "name": "bromocriptine",
    "comment": "Rx",
    "other_names": [
        "Cycloset",
        "Parlodel"
    ],
    "classes": [
        "Antiparkinson Agents",
        "Dopamine Agonists",
        "Hyperprolactinemia",
        "Metabolic & Endocrine",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/cycloset-parlodel-bromocriptine-343124",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women with type 2 diabetes; prolonged experience with bromocriptine use in pregnant women for other indications over several decades, based on data from published clinical trials, case reports, and epidemiological studies, have not established a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Only a trace amount of bromocriptine was shown to be transported across placenta in vitro in a published ex vivo human placental perfusion model; there are risks to mother and fetus associated with poorly controlled diabetes in pregnancy; should be used during pregnancy only if clearly necessary",
            "Parlodel: Avoid use during lactation in postpartum women"
        ],
        "specific": [
            {
                "type": "Parlodel",
                "description": [
                    "Safety of Parlodel treatment during pregnancy to the mother and fetus has not been established",
                    "If pregnancy occurs during Parlodel administration, careful observation of these patients is mandatory",
                    "Prolactin-secreting adenomas may expand and compression of optic/other cranial nerves may occur, emergency pituitary surgery becoming necessary; in most cases, the compression resolves following delivery",
                    "Reinitiation of Parlodel treatment has been reported to produce improvement in the visual fields of patients in whom nerve compression has occurred during pregnancy",
                    "In patients being treated for metabolic-endocrine#hyperprolactinemia, Parlodel should be withdrawn when pregnancy is diagnosed",
                    "  ",
                    "  ",
                    "Patients who subsequently become pregnant, determine whether continuing therapy is medically necessary or can discontinues",
                    "If it is continued, discontinue therapy in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of Parlodel is considered to be medically contraindicated"
                ]
            },
            {
                "type": "Cycloset",
                "description": [
                    "  ",
                    "  ",
                    "Studies in which bromocriptine mesylate was administered orally during period of organogenesis, increased prenatal mortality occurred in rats and rabbits at maternally toxic dosages that were more than 24-times human dose of 4.8 mg/day based on body surface area; no adverse developmental outcomes were observed in monkeys administered bromocriptine mesylate orally during various periods of gestation at doses up to 10-times a human dose of 4.8 mg daily",
                    "Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications; poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia related morbidity"
                ]
            },
            {
                "type": "Cycloset",
                "description": [
                    "  ",
                    "  ",
                    "Studies in which bromocriptine mesylate was administered orally during period of organogenesis, increased prenatal mortality occurred in rats and rabbits at maternally toxic dosages that were more than 24-times human dose of 4.8 mg/day based on body surface area; no adverse developmental outcomes were observed in monkeys administered bromocriptine mesylate orally during various periods of gestation at doses up to 10-times a human dose of 4.8 mg daily",
                    "Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications; poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia related morbidity"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Parlodel: Avoid use during lactation in postpartum women"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "Dosage forms for Cycloset and Parlodel and not interchangeable",
                "Discontinuation of treatment should be undertaken gradually whenever possible, even if patient is to remain on levodopa; a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, reported in association with rapid dose reduction, withdrawal of, or changes in antiparkinsonian therapy",
                "Use with caution in patients with cardiovascular disease, dementia, hepatic impairment, and peptic ulcer disease",
                "Symptoms including apathy, anxiety, depression, fatigue, insomnia, sweating, and pain reported during taper or after discontinuation of dopamine agonists; these symptoms generally do not respond to levodopa; prior to discontinuation of therapy, patients should be informed about potential withdrawal symptoms, and closely monitored during and after discontinuation of treatment; in case of severe withdrawal symptoms, re-administration of a dopamine agonist at lowest effective dose may be considered"
            ],
            "specific": [
                {
                    "type": "Somnolence",
                    "description": [
                        "Somnolence, and episodes of sudden sleep onset has been reported, particularly in patients with Parkinsonâ€™s disease",
                        "Inform and advise not to drive or operate machines during treatment; dose reduction or termination of therapy may be considered",
                        "During the first days of treatment, hypotensive reactions may occasionally occur and result in reduced alertness, particular care should be exercised when driving a vehicle or operating machinery"
                    ]
                },
                {
                    "type": "Parlodel",
                    "description": [
                        "Avoid use in patients with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption",
                        "Used with caution in patients with a history of psychosis or cardiovascular disease",
                        "In patients undergoing treatment for macroadenoma-related metabolic-endocrine#hyperprolactinemia or who have undergone transsphenoidal surgery, a persistent watery nasal discharge may be sign of CSF rhinorrhea",
                        "Visual field impairment is a known complication of macroprolactinoma; Parlodel therapy may lead to a reduction in metabolic-endocrine#hyperprolactinemia and often to a resolution of the visual impairment; monitor visual fields in patients with macroprolactinoma",
                        "Cold-sensitive digital vasospasm has been observed in some acromegalic patients; response is reversible by dose reduction of Parlodel and may be prevented by keeping the fingers warm",
                        "Cases of severe gastrointestinal bleeding from peptic ulcers have been reported; patients with a history of peptic ulcer or gastrointestinal bleeding should be observed carefully during treatment with Parlodel",
                        "Possible tumor expansion while receiving Parlodel therapy has been reported; all patients should be carefully monitored and, if evidence of tumor expansion develops, discontinuation of treatment and alternative procedures considered",
                        "High doses of Parlodel may be associated with confusion and mental disturbances; parkinsonian patients may manifest mild degrees of dementia, caution should be used when treating such patients",
                        "Auditory or visual hallucinations may occur when administered alone or concomitantly with levodopa; hallucinations usually resolve with dosage reduction; occasionally, discontinue therapy",
                        "Postmarketing reports suggest that patients treated with anti-Parkinson medications can experience intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and other intense urges",
                        "History of MI and a residual atrial, nodal or ventricular arrhythmia, especially with Parkinson disease",
                        "Retroperitoneal fibrosis has been reported in a few patients receiving long-term therapy",
                        "Use of drug for prevention of physiological lactation not recommended",
                        "Hypertension",
                        "Hypertension have been reported, sometimes at the initiation of therapy, but often developing in the second week of therapy; periodic blood pressure monitoring, during the first weeks of therapy is prudent",
                        "Seizures have also been reported both with and without the prior development of hypertension; stroke have been reported mostly in postpartum patients whose prenatal and obstetric courses had been uncomplicated",
                        "Use of the drug in patients with uncontrolled hypertension is not recommended (see Contraindications [Parlodel])",
                        "Exercise caution when administering Parlodel therapy concomitantly with other medications known to lower blood pressure",
                        "If hypertension, severe, progressive, or unremitting headache (with or without visual disturbance), or evidence of CNS toxicity develops, evaluate patient and therapy should be discontinued",
                        "Parkinsonâ€™s disease",
                        "Hallucinations: occasionally, discontinuation of therapy is required; rarely, after high doses, hallucinations have persisted for several weeks following discontinuation of drug",
                        "Fibrosis: Retroperitoneal fibrosis has been reported in a few patients receiving long-term therapy (2 to 10 years) with drug in doses ranging from 30-140 mg daily",
                        "Safety during long-term use for more than 2 years at the doses required for parkinsonism has not been established",
                        "As with any chronic therapy, periodic evaluation of hepatic, hematopoietic, cardiovascular, and renal function is recommended; symptomatic hypotension can occur and, therefore, caution should be exercised when treating patients receiving antihypertensive drugs",
                        "As with levodopa, caution should be exercised when administering therapy to patients with a history of myocardial infarction who have a residual atrial, nodal, or ventricular arrhythmia",
                        "Melanoma",
                        "Epidemiological studies have shown that patients with Parkinsonâ€™s disease have a higher risk (2- approximately 6-fold higher) of developing melanoma than the general population",
                        "Whether the increased risk observed was due to Parkinsonâ€™s disease or other factors, such as drugs used to treat Parkinsonâ€™s disease, is unclear",
                        "Patients and providers are advised to monitor for melanomas frequently and on a regular basis when using drug for any indication",
                        "Ideally, periodic skin examinations should be performed by appropriately qualified individuals (eg, dermatologists)"
                    ]
                },
                {
                    "type": "Cycloset",
                    "description": [
                        "Somnolence may occur; inform patients should be made aware of this potential side effect, particularly when initiating therapy; patients experiencing somnolence should refrain from driving or operating heavy machinery",
                        "Fibrotic valve thickening (eg, aortic, mitral, tricuspid), possibly due to excess serotonin activity, usually associated with long-term, chronic use of ergot alkaloids and derivatives reported",
                        "Serious and life-threatening adverse reactions including hypertension, myocardial infarction, seizures, stroke and psychosis reported postmarketing in postpartum women administered treatment for inhibition of lactation",
                        "Dopamine receptor antagonists",
                        "Dopamine receptor antagonists, including neuroleptic agents that have dopamine D2 receptor antagonist properties (eg, clozapine, olanzapine, ziprasidone), may reduce the effectiveness of Cycloset and Cycloset may reduce the effectiveness of these agents; concomitant use with dopamine receptor antagonists, including neuroleptic drugs, is not recommended",
                        "Other dopamine receptor agonists are indicated for the treatment of Parkinsonâ€™s disease, metabolic-endocrine#hyperprolactinemia, restless leg syndrome, acromegaly, and other disorders; effectiveness and safety of Cycloset in patients currently treated with other dopamine receptor agonists is unknown; concomitant use is not recommended",
                        "Hypotension",
                        "Hypotension, including orthostatic hypotension, can occur, particularly upon Cycloset initiation and with dose escalation",
                        "Assess orthostatic vital signs prior to initiation of Cycloset and periodically thereafter; during early treatment, patients should be advised to make slow postural changes and to avoid situations that could lead to serious injury if syncope was to occur",
                        "Use caution in patients taking anti-hypertensive medication"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "almotriptan",
            "description": {
                "common": "bromocriptine, almotriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eletriptan",
            "description": {
                "common": "bromocriptine, eletriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "bromocriptine, frovatriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "glyceryl trinitrate pr",
            "description": {
                "common": "bromocriptine decreases effects of glyceryl trinitrate pr by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "naratriptan",
            "description": {
                "common": "bromocriptine, naratriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin IV",
            "description": {
                "common": "bromocriptine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin sublingual",
            "description": {
                "common": "bromocriptine decreases effects of nitroglycerin sublingual by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin topical",
            "description": {
                "common": "bromocriptine decreases effects of nitroglycerin topical by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin transdermal",
            "description": {
                "common": "bromocriptine decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin translingual",
            "description": {
                "common": "bromocriptine decreases effects of nitroglycerin translingual by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "bromocriptine, sumatriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "bromocriptine, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "bromocriptine, zolmitriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Vasoconstrictive effects of triptans and bromocriptine may be additive. Drugs should not be used within 24h of one another."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concomitant use is warranted, carefully monitor, particularly during treatment initiation and dose adjustment. Discontinue oliceridine if serotonin syndrome is suspected."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride, bromocriptine.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabergoline",
            "description": {
                "common": "cabergoline, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dihydroergotamine, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "dihydroergotamine intranasal, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz increases levels of bromocriptine by decreasing metabolism. Avoid or Use Alternate Drug. Competitive inhibition of CYP3A4 might lead to vasospasm and ischemia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "ergoloid mesylates, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergotamine",
            "description": {
                "common": "ergotamine, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "bromocriptine will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine",
            "description": {
                "common": "loxapine decreases effects of bromocriptine by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled decreases effects of bromocriptine by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "methylergonovine, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "bromocriptine, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "bromocriptine and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "bromocriptine, phenylephrine PO. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "prochlorperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, bromocriptine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "bromocriptine, serdexmethylphenidate/dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thiothixene",
            "description": {
                "common": "thiothixene decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifampridine",
            "description": {
                "common": "bromocriptine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "apomorphine and bromocriptine both increase  dopaminergic effects. Use Caution/Monitor. Combination may enhance  efficacy. Monitor for hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "bromocriptine will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "bromocriptine will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "bromocriptine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "bromocriptine, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabergoline",
            "description": {
                "common": "bromocriptine and cabergoline both increase  dopaminergic effects. Use Caution/Monitor. Combining drugs may be therapeutic in patients with Parkinsonism. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "bromocriptine, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib increases levels of bromocriptine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of bromocriptine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "bromocriptine increases levels of cyclosporine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "bromocriptine and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "bromocriptine, dexmethylphenidate.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "bromocriptine, dextroamphetamine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and bromocriptine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "bromocriptine, dobutamine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopamine",
            "description": {
                "common": "bromocriptine and dopamine both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "duvelisib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. will increase the level or effect of"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "elagolix will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of bromocriptine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, bromocriptine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "bromocriptine, ephedrine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "bromocriptine, epinephrine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base increases levels of bromocriptine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate increases levels of bromocriptine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate increases levels of bromocriptine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate increases levels of bromocriptine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "bromocriptine will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "bromocriptine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone increases levels of bromocriptine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "bromocriptine will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "bromocriptine, isoproterenol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "istradefylline will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lanreotide",
            "description": {
                "common": "lanreotide increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Somatropin may increase CYP450 enzymes and, therefore, suppression of growth hormone secretion by somatostatin analogs including pasireotide may decrease the metabolic clearance of compounds metabolized by CYP450 enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "bromocriptine will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of bromocriptine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "bromocriptine and levodopa both increase  dopaminergic effects. Use Caution/Monitor. Combining drugs may be therapeutic in patients with Parkinsonism and may allow for reduced levodopa doses. Dosages should be carefully titrated during concomitant treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "bromocriptine, lisdexamfetamine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "bromocriptine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone decreases effects of bromocriptine by pharmacodynamic antagonism. Use Caution/Monitor. Antipsychotics may diminish  the therapeutic effect of anti-parkinson's agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "bromocriptine, methamphetamine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "bromocriptine, methylphenidate.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide decreases levels of bromocriptine by pharmacodynamic antagonism. Use Caution/Monitor. Avoid combination if possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "bromocriptine will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.  Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midodrine",
            "description": {
                "common": "bromocriptine, midodrine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of bromocriptine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "bromocriptine, norepinephrine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "octreotide",
            "description": {
                "common": "octreotide increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Somatropin may increase CYP450 enzymes and, therefore, suppression of growth hormone secretion by somatostatin analogs including pasireotide may decrease the metabolic clearance of compounds metabolized by CYP450 enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "pasireotide increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Somatropin may increase CYP450 enzymes and, therefore, suppression of growth hormone secretion by somatostatin analogs including pasireotide may decrease the metabolic clearance of compounds metabolized by CYP450 enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentermine",
            "description": {
                "common": "bromocriptine, phentermine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine",
            "description": {
                "common": "bromocriptine, phenylephrine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramipexole",
            "description": {
                "common": "bromocriptine and pramipexole both increase  dopaminergic effects. Use Caution/Monitor. Combining drugs may be therapeutic in patients with Parkinsonism. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "bromocriptine, pseudoephedrine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "bromocriptine and ropinirole both increase  dopaminergic effects. Use Caution/Monitor. Combining drugs may be therapeutic in patients with Parkinsonism. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "bromocriptine, serdexmethylphenidate/dexmethylphenidate.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Hypertension, V tach."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solriamfetol",
            "description": {
                "common": "bromocriptine and solriamfetol both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, bromocriptine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "bromocriptine increases levels of tacrolimus by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "bromocriptine will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "bromocriptine will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "bromocriptine will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Monotherapy Nausea",
            "percent": "32.5"
        },
        {
            "name": "Rhinitis",
            "percent": "13.8"
        },
        {
            "name": "Headache",
            "percent": "12.5"
        },
        {
            "name": "Asthenia",
            "percent": "12.5"
        },
        {
            "name": "Dizziness",
            "percent": "12.5"
        },
        {
            "name": "Constipation",
            "percent": "11.3"
        },
        {
            "name": "Nausea",
            "percent": "32.5"
        },
        {
            "name": "Rhinitis",
            "percent": "13.8"
        },
        {
            "name": "Headache",
            "percent": "12.5"
        },
        {
            "name": "Asthenia",
            "percent": "12.5"
        },
        {
            "name": "Dizziness",
            "percent": "12.5"
        },
        {
            "name": "Constipation",
            "percent": "11.3"
        },
        {
            "name": "Adjunct to sulfonylurea Nausea",
            "percent": "25.4"
        },
        {
            "name": "Asthenia",
            "percent": "18.9"
        },
        {
            "name": "Headache",
            "percent": "16.8"
        },
        {
            "name": "Dizziness",
            "percent": "11.9"
        },
        {
            "name": "Rhinitis",
            "percent": "10.7"
        },
        {
            "name": "Nausea",
            "percent": "25.4"
        },
        {
            "name": "Asthenia",
            "percent": "18.9"
        },
        {
            "name": "Headache",
            "percent": "16.8"
        },
        {
            "name": "Dizziness",
            "percent": "11.9"
        },
        {
            "name": "Rhinitis",
            "percent": "10.7"
        },
        {
            "name": "Adjunct to diet or",
            "percent": "2"
        },
        {
            "name": "antidiabetic medications",
            "percent": "32.2"
        },
        {
            "name": "eg",
            "percent": "14.8"
        },
        {
            "name": "metformin",
            "percent": "13.9"
        },
        {
            "name": "insulin secretagogues",
            "percent": "11.4"
        },
        {
            "name": "and",
            "percent": "32.2"
        },
        {
            "name": "or insulin",
            "percent": "14.8"
        },
        {
            "name": "Nausea",
            "percent": "13.9"
        },
        {
            "name": "Dizziness",
            "percent": "11.4"
        },
        {
            "name": "Fatigue",
            "percent": "49"
        },
        {
            "name": "Headache",
            "percent": "19"
        },
        {
            "name": "Nausea",
            "percent": "17"
        },
        {
            "name": "Dizziness",
            "percent": "49"
        },
        {
            "name": "Fatigue",
            "percent": "19"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Hyperprolactinemic indications Nausea",
            "percent": "18"
        },
        {
            "name": "Headache",
            "percent": "14"
        },
        {
            "name": "Dizziness",
            "percent": "18"
        },
        {
            "name": "Nausea",
            "percent": "14"
        },
        {
            "name": "Headache",
            "percent": "10"
        },
        {
            "name": "Dizziness",
            "percent": "8.8"
        },
        {
            "name": "Acromegaly Nausea",
            "percent": "7.5"
        },
        {
            "name": "Constipation",
            "percent": "7.5"
        },
        {
            "name": "Nausea",
            "percent": "6.3"
        },
        {
            "name": "Constipation",
            "percent": "6.3"
        },
        {
            "name": "Monotherapy Sinusitis",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": "10"
        },
        {
            "name": "Amblyopia",
            "percent": "8.8"
        },
        {
            "name": "Dyspepsia",
            "percent": "7.5"
        },
        {
            "name": "Vomiting",
            "percent": "7.5"
        },
        {
            "name": "Infection",
            "percent": "6.3"
        },
        {
            "name": "Anorexia",
            "percent": "6.3"
        },
        {
            "name": "Sinusitis",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": "9.8"
        },
        {
            "name": "Amblyopia",
            "percent": "9.4"
        },
        {
            "name": "Dyspepsia",
            "percent": "8.2"
        },
        {
            "name": "Vomiting",
            "percent": "7.4"
        },
        {
            "name": "Infection",
            "percent": "6.6"
        },
        {
            "name": "Anorexia",
            "percent": "5.3"
        },
        {
            "name": "Adjunct to sulfonylurea Constipation",
            "percent": "5.3"
        },
        {
            "name": "Flu syndrome",
            "percent": "9.8"
        },
        {
            "name": "Cold",
            "percent": "9.4"
        },
        {
            "name": "Sinusitis",
            "percent": "8.2"
        },
        {
            "name": "Somnolence",
            "percent": "7.4"
        },
        {
            "name": "Vomiting",
            "percent": "6.6"
        },
        {
            "name": "Amblyopia",
            "percent": "5.3"
        },
        {
            "name": "Constipation",
            "percent": "5.3"
        },
        {
            "name": "Flu syndrome",
            "percent": "2"
        },
        {
            "name": "Cold",
            "percent": "8.1"
        },
        {
            "name": "Sinusitis",
            "percent": "8.1"
        },
        {
            "name": "Somnolence",
            "percent": "5.8"
        },
        {
            "name": "Vomiting",
            "percent": "8.1"
        },
        {
            "name": "Amblyopia",
            "percent": "8.1"
        },
        {
            "name": "Adjunct to diet or",
            "percent": "5.8"
        },
        {
            "name": "antidiabetic medications",
            "percent": "7"
        },
        {
            "name": "eg",
            "percent": "5"
        },
        {
            "name": "metformin",
            "percent": "5"
        },
        {
            "name": "insulin secretagogues",
            "percent": "4"
        },
        {
            "name": "and",
            "percent": "3"
        },
        {
            "name": "or insulin",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Constipation",
            "percent": "7"
        },
        {
            "name": "Vomiting",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": "5"
        },
        {
            "name": "Constipation",
            "percent": "4"
        },
        {
            "name": "Hyperprolactinemic indications Fatigue",
            "percent": "3"
        },
        {
            "name": "Lightheadedness",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "Abdominal cramps",
            "percent": "3"
        },
        {
            "name": "Nasal congestion",
            "percent": "6"
        },
        {
            "name": "Constipation",
            "percent": "4"
        },
        {
            "name": "Diarrhea",
            "percent": "4"
        },
        {
            "name": "Drowsiness",
            "percent": "4"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Lightheadedness",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Abdominal cramps",
            "percent": "2"
        },
        {
            "name": "Nasal congestion",
            "percent": "2"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Drowsiness",
            "percent": "2"
        },
        {
            "name": "Acromegaly Postural",
            "percent": "6"
        },
        {
            "name": "orthostatic hypotension",
            "percent": "4"
        },
        {
            "name": "Anorexia",
            "percent": "4"
        },
        {
            "name": "Dry mouth",
            "percent": "4"
        },
        {
            "name": "nasal stuffiness",
            "percent": "3"
        },
        {
            "name": "Indigestion",
            "percent": "3"
        },
        {
            "name": "dyspepsia",
            "percent": "2"
        },
        {
            "name": "Digital vasospasm",
            "percent": "2"
        },
        {
            "name": "Drowsiness",
            "percent": "2"
        },
        {
            "name": "tiredness",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Gastrointestinal bleeding",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "10"
        },
        {
            "name": "Exacerbation of Raynaud syndrome",
            "percent": "8"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Syncope",
            "percent": "3"
        },
        {
            "name": "Postural",
            "percent": "1"
        },
        {
            "name": "orthostatic hypotension",
            "percent": "10"
        },
        {
            "name": "Anorexia",
            "percent": "8"
        },
        {
            "name": "Dry mouth",
            "percent": "7"
        },
        {
            "name": "nasal stuffiness",
            "percent": "3"
        },
        {
            "name": "Indigestion",
            "percent": "1"
        },
        {
            "name": "dyspepsia",
            "percent": "0.7"
        },
        {
            "name": "Digital vasospasm",
            "percent": "0.4"
        },
        {
            "name": "Drowsiness",
            "percent": "0.4"
        },
        {
            "name": "tiredness",
            "percent": "0.7"
        },
        {
            "name": "Vomiting",
            "percent": "0.4"
        },
        {
            "name": "Gastrointestinal bleeding",
            "percent": "0.4"
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Exacerbation of Raynaud syndrome",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Postpartum Headache",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Postpartum Syncope",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Cramps",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Cramps",
            "percent": null
        },
        {
            "name": "Parkinson disease Most common",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "abnormal involuntary movements",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "confusion",
            "percent": null
        },
        {
            "name": "on",
            "percent": null
        },
        {
            "name": "off",
            "percent": null
        },
        {
            "name": "phenomenon",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "drowsiness",
            "percent": null
        },
        {
            "name": "faintness",
            "percent": null
        },
        {
            "name": "fainting",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "abdominal discomfort",
            "percent": null
        },
        {
            "name": "visual disturbance",
            "percent": null
        },
        {
            "name": "ataxia",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "shortness of breath",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "and vertigo Less common",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "blepharospasm",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "dysphagia",
            "percent": null
        },
        {
            "name": "edema of the feet and ankles",
            "percent": null
        },
        {
            "name": "erythromelalgia",
            "percent": null
        },
        {
            "name": "epileptiform seizure",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "lethargy",
            "percent": null
        },
        {
            "name": "mottling of skin",
            "percent": null
        },
        {
            "name": "nasal stuffiness",
            "percent": null
        },
        {
            "name": "nervousness",
            "percent": null
        },
        {
            "name": "nightmares",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "skin rash",
            "percent": null
        },
        {
            "name": "urinary frequency",
            "percent": null
        },
        {
            "name": "urinary incontinence",
            "percent": null
        },
        {
            "name": "urinary retention",
            "percent": null
        },
        {
            "name": "and rarely",
            "percent": null
        },
        {
            "name": "signs and symptoms of ergotism such as tingling of fingers",
            "percent": null
        },
        {
            "name": "cold feet",
            "percent": null
        },
        {
            "name": "numbness",
            "percent": null
        },
        {
            "name": "muscle cramps of feet and legs or exacerbation of Raynaud syndrome",
            "percent": null
        },
        {
            "name": "Most common",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "abnormal involuntary movements",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "confusion",
            "percent": null
        },
        {
            "name": "on",
            "percent": null
        },
        {
            "name": "off",
            "percent": null
        },
        {
            "name": "phenomenon",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "drowsiness",
            "percent": null
        },
        {
            "name": "faintness",
            "percent": null
        },
        {
            "name": "fainting",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "abdominal discomfort",
            "percent": null
        },
        {
            "name": "visual disturbance",
            "percent": null
        },
        {
            "name": "ataxia",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        },
        {
            "name": "shortness of breath",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "and vertigo",
            "percent": null
        },
        {
            "name": "Less common",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "blepharospasm",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "dysphagia",
            "percent": null
        },
        {
            "name": "edema of the feet and ankles",
            "percent": null
        },
        {
            "name": "erythromelalgia",
            "percent": null
        },
        {
            "name": "epileptiform seizure",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "lethargy",
            "percent": null
        },
        {
            "name": "mottling of skin",
            "percent": null
        },
        {
            "name": "nasal stuffiness",
            "percent": null
        },
        {
            "name": "nervousness",
            "percent": null
        },
        {
            "name": "nightmares",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "skin rash",
            "percent": null
        },
        {
            "name": "urinary frequency",
            "percent": null
        },
        {
            "name": "urinary incontinence",
            "percent": null
        },
        {
            "name": "urinary retention",
            "percent": null
        },
        {
            "name": "and rarely",
            "percent": null
        },
        {
            "name": "signs and symptoms of ergotism such as tingling of fingers",
            "percent": null
        },
        {
            "name": "cold feet",
            "percent": null
        },
        {
            "name": "numbness",
            "percent": null
        },
        {
            "name": "muscle cramps of feet and legs or exacerbation of Raynaud syndrome",
            "percent": null
        },
        {
            "name": "Hallucinations",
            "percent": null
        },
        {
            "name": "Fibrotic",
            "percent": null
        },
        {
            "name": "related complications",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "retroperitoneal fibrosis",
            "percent": null
        },
        {
            "name": "pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "pleural effusion",
            "percent": null
        },
        {
            "name": "pleural thickening",
            "percent": null
        },
        {
            "name": "pericarditis",
            "percent": null
        },
        {
            "name": "and pericardial effusions",
            "percent": null
        },
        {
            "name": "Psychotic and psychiatric disorders",
            "percent": null
        },
        {
            "name": "Stroke",
            "percent": null
        },
        {
            "name": "Neuroleptic",
            "percent": null
        },
        {
            "name": "like malignant syndrome",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "myocardial infarction",
            "percent": null
        },
        {
            "name": "seizures",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "psychomotor agitation",
            "percent": null
        },
        {
            "name": "excitation",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "psychotic disorders",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "libido increase",
            "percent": null
        },
        {
            "name": "hypersexuality",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "drowsiness",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "dyskinesia",
            "percent": null
        },
        {
            "name": "somnolence",
            "percent": null
        },
        {
            "name": "paraesthesia",
            "percent": null
        },
        {
            "name": "excess daytime somnolence",
            "percent": null
        },
        {
            "name": "sudden onset of sleep",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Visual disturbance",
            "percent": null
        },
        {
            "name": "vision blurred",
            "percent": null
        },
        {
            "name": "Ear and labyrinth disorders",
            "percent": null
        },
        {
            "name": "Tinnitus",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Pericardial effusion",
            "percent": null
        },
        {
            "name": "constrictive pericarditis",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "bradycardia",
            "percent": null
        },
        {
            "name": "arrhythmia",
            "percent": null
        },
        {
            "name": "cardiac valve fibrosis",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "orthostatic hypotension",
            "percent": null
        },
        {
            "name": "very rarely leading to syncope",
            "percent": null
        },
        {
            "name": "reversible pallor of fingers and toes induced by cold",
            "percent": null
        },
        {
            "name": "especially in patients with history of Raynaud phenomenon",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Nasal congestion",
            "percent": null
        },
        {
            "name": "pleural effusion",
            "percent": null
        },
        {
            "name": "pleural fibrosis",
            "percent": null
        },
        {
            "name": "pleurisy",
            "percent": null
        },
        {
            "name": "pulmonary fibrosis",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "constipation",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "dry mouth",
            "percent": null
        },
        {
            "name": "diarrhoea",
            "percent": null
        },
        {
            "name": "abdominal pain",
            "percent": null
        },
        {
            "name": "retroperitoneal fibrosis",
            "percent": null
        },
        {
            "name": "gastrointestinal ulcer",
            "percent": null
        },
        {
            "name": "gastrointestinal hemorrhage",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Allergic skin reactions",
            "percent": null
        },
        {
            "name": "hair loss",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Leg cramps",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "peripheral edema",
            "percent": null
        },
        {
            "name": "apathy",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "depression",
            "percent": null
        },
        {
            "name": "insomnia",
            "percent": null
        },
        {
            "name": "sweating",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "a syndrome resembling Neuroleptic Malignant Syndrome",
            "percent": null
        },
        {
            "name": "NMS",
            "percent": null
        },
        {
            "name": "on abrupt withdrawal of Parlodel",
            "percent": null
        }
    ]
}